BCRX Stock Summary and Trading Ideas (Biocryst Pharmaceuticals | NASDAQ:BCRX)

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Biocryst Pharmaceuticals trades on the NASDAQ stock market under the symbol BCRX.

As of November 10, 2026, BCRX stock price declined to $7.53 with 2,628,497 million shares trading.

BCRX has a beta of 0.67, meaning it tends to be less sensitive to market movements. BCRX has a correlation of 0.03 to the broad based SPY ETF.

BCRX has a market cap of $1.92 billion. This is considered a Small Cap stock.

Last quarter Biocryst Pharmaceuticals reported $180 million in Revenue and $.14 earnings per share. This beat revenue expectation by $14 million and exceeded earnings estimates by $.03.

In the last 3 years, BCRX traded as high as $11.31 and as low as $4.03.

The top ETF exchange traded funds that BCRX belongs to (by Net Assets): VTI, XBI, IWM, VB, VXF.

BCRX has underperformed the market in the last year with a price return of +6.2% while the SPY ETF gained +12.9%. BCRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -19.7% and -4.4%, respectively, while the SPY returned -2.8% and -2.0%, respectively.

BCRX support price is $7.44 and resistance is $7.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCRX shares will trade within this expected range on the day.